超声造影在不确定性小实性肾肿块及囊性肾病变风险分层中的增益价值
该回顾性研究纳入237例患者共241个病灶,评估超声造影(CEUS)对CT/MRI上不确定性小实性肾肿块(排除富脂AML)和囊性肾病变(CRM)的诊断准确性,并按照2019版Bosniak分类进行风险分层。结果显示,CEUS动脉期相对于肾皮质低增强预测恶性的特异度达97.4%、阳性预测值98.2%,观察者间kappa为0.95;100% vs 25%,P<0.0001)。
要点
- CEUS动脉期低增强(相对于肾皮质)对排除富脂AML后的小实性肾肿块诊断RCC具有高特异度(97.4%)和高PPV(98.2%)。
- 在囊性肾病变的Bosniak 2019分类中,CEUS诊断恶性的敏感度和NPV显著优于CT/MRI(100% vs 60%)。
- CEUS可减少CT/MRI判为Bosniak IIF的病变数量,将其重新归类为II或III/IV类。
核心结论
- 在排除富脂AML后,CEUS动脉期相对于肾皮质低增强对小实性肾肿块诊断RCC具有高特异度和PPV。
- 与CT/MRI相比,CEUS在囊性肾病变中诊断恶性的敏感度和NPV显著更高。
- CEUS按照Bosniak 2019分类评估囊性肾病变的观察者间一致性优于CT/MRI。
研究设计与样本
- 单中心回顾性研究,纳入237例患者共241个病灶。
- 病灶包括161个病理证实的小实性肾肿块(122恶性、39良性)、29个病理证实的囊性肾病变及51个随访≥18个月的囊性肾病变。
- 两名放射科医师盲法在CT/MRI上按2019版Bosniak分类评估囊性肾病变,另两名放射科医师在CEUS上评估小实性肾肿块的动脉期增强(相对于肾皮质)并按2019版Bosniak分类评估囊性肾病变。
- 参考标准为病理或随访≥18个月。
诊断标准与关键数值
- 小实性肾肿块(排除富脂AML):CEUS动脉期增强低于肾皮质预测恶性的特异度97.4%(38/39,95%CI 85.6-99.9%),PPV 98.2%(54/55,95%CI 90.4-99.9%),观察者间kappa 0.95。
- 病理证实的囊性肾病变:CEUS的NPV 100%(2/2,95%CI 17.8-100%),CT/MRI为25%(2/8,95%CI 4.4-59.1%),P<0.0001。
- 病理证实的囊性肾病变:CEUS与CT/MRI特异度均为50%,PPV分别为88.2%(15/17,95%CI 65.7-97.9%)与81.8%(9/11,95%CI 52.3-96.8%),P=0.586。
- Bosniak分类观察者间kappa:CEUS为0.92,CT/MRI为0.68,P=0.009。
临床应用与阅片要点
- 对于CT/MRI上定性困难的小实性肾肿块(无明确强化或宏观脂肪),可加做CEUS,动脉期相对于肾皮质低增强高度提示恶性。
- 在囊性肾病变的Bosniak分类评估中,CEUS可提高诊断恶性的敏感度和NPV,减少CT/MRI判为IIF的病变数量。
- CEUS评估Bosniak分类的观察者间一致性较高,可能有助于标准化报告。
局限性
- 回顾性单中心设计,可能存在选择偏倚。
- 囊性肾病变中病理证实的样本量较小(29个),部分亚组置信区间较宽。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate accuracy of contrast-enhanced ultrasound (CEUS) to characterize indeterminate small solid renal masses (sSRMs), excluding lipid-rich AMLs, and cystic renal masses (CRMs) according to the proposed Bosniak Classification 2019 MATERIALS AND METHODS: CEUS of pathology-proven CRMs and sSRMs (without definite enhancement or macroscopic fat on CT/MRI), and CRMs with ≥18 months follow-up were retrospectively reviewed. Two radiologists blindly categorized CRMs according to new Bosniak Classification on CT/MRI. On CEUS, two other radiologists evaluated arterial-phase enhancement of sSRMs relative to renal cortex and categorized CRMs following new Bosniak Classification. Fisher's exact/chi-squared test was used to compare categorical variables, and Cohen κ statistics for inter-observer agreement RESULTS: A total of 237 patients had 241 lesions: 161 pathology-proven sSRMs (122 malignant and 39 benign), 29 pathology-proven CRMs, 51 CRMs with adequate follow-up. Arterial-phase enhancement < renal cortex predicted malignancy with specificity of 97.4% (38/39) (CI 85.6-99.9%), and positive predictive value (PPV) of 98.2% (54/55) (CI 90.4-99.9%). Inter-observer kappa was 0.95. In pathology-proven CRMS, sensitivity of CEUS vs CT/MRI was 100% (15/15) (CI 79.6-100%) vs 60% (9/15) (CI 35.8-80.1%) (p value = .002) and negative predictive value (NPV) 100% (2/2) (CI 17.8-100%) vs 25% (2/8 ) (CI 4.4-59.1%) (p value < 0.0001), with similar specificity (50%) and PPV- 88.2% (15/17) (CI 65.7-97.9%) vs 81.8% (9/11) (CI 52.3-96.8%) ( p value = 0.586). Bosniak Classification inter-observer kappa was 0.92 for CEUS vs 0.68 for CT/MRI (p value = 0.009).
CONCLUSION: In our cohort, CEUS had high specificity and PPV to diagnose RCC in sSRMs excluding lipid-rich AML. CEUS had significantly higher sensitivity/NPV to diagnose malignancy in CRMs as compared to CT/MRI.
KEY POINTS: • Once lipid-rich AML is excluded by the other modalities, sSRM arterial phase hypo-enhancement relative to renal cortex on CEUS yielded high specificity (97.4%) and PPV (98.2%) to diagnose RCC. • When applying the proposed Bosniak Classification 2019, CEUS showed higher sensitivity compared to CT/MRI (100% vs 60%), p value=.0024, in the stratification of cystic renal masses to diagnose malignancy. • CEUS may reduce the number of CT/MRI Bosniak IIF lesions by assigning them to either II or III/IV categories.
引用
- Elbanna KY, Jang HJ, Kim TK, et al. The added value of contrast-enhanced ultrasound in evaluation of indeterminate small solid renal masses and risk stratification of cystic renal lesions. Eur Radiol. 2021. PMID: 33912992. doi:10.1007/s00330-021-07964-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。